You just read:

PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) for Nonsense Mutation Duchenne Muscular Dystrophy

News provided by

PTC Therapeutics, Inc.

17 Oct, 2016, 08:00 ET